Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.56
+0.04000.61%
Post-market: 6.560.00000.00%16:22 EDT
Volume:956.82K
Turnover:6.24M
Market Cap:529.90M
PE:-3.25
High:6.59
Open:6.46
Low:6.43
Close:6.52
Loading ...

Kura Reports Dosing in Phase 1 Ziftomenib Combination Trial

MT Newswires Live
·
28 Apr

Kura Oncology’s Strategic Advancements and Market Potential Justify Buy Rating

TIPRANKS
·
28 Apr

Kura Oncology’s Strategic Advances and Promising Trials Garner Buy Rating from Analyst

TIPRANKS
·
28 Apr

BRIEF-Kura Oncology Announces First Patients Dosed In Phase 1 Combination Trial Of Ziftomenib For The Treatment Of Advanced Gist

Reuters
·
28 Apr

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

GlobeNewswire
·
28 Apr

Kura Oncology to Report First Quarter 2025 Financial Results

GlobeNewswire
·
24 Apr

Kura Oncology’s Strategic Milestones and Financial Strength Bolster Buy Rating

TIPRANKS
·
09 Apr

Kura Oncology’s Promising Developments and Strategic Expansion Justify Buy Rating

TIPRANKS
·
08 Apr

Strategic Advancements and Early NDA Submission Drive Buy Rating for Kura Oncology

TIPRANKS
·
08 Apr

Kura Oncology Submits Ziftomenib NDA to FDA for Treating Acute Myeloid Leukemia

MT Newswires Live
·
08 Apr

Kura Oncology Inc: Expects to Receive Notification From FDA on This Preliminary Evaluation in Q2 of 2025

THOMSON REUTERS
·
08 Apr

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

THOMSON REUTERS
·
08 Apr

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

GlobeNewswire
·
08 Apr

BRIEF-Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Apr

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
04 Apr

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Apr

Press Release: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
04 Apr

Kura Oncology Announces Preclinical Data for Ko-2806 Selected for Oral Presentation at the 2025 Aacr Annual Meeting

THOMSON REUTERS
·
26 Mar

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

GlobeNewswire
·
26 Mar

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
07 Mar